In this work, we started from the promising properties of pioglitazone, a marketed drug for diabetes, and repositioned it as an MAO-B selective competitive inhibitor, endowed with remarkable neuroprotective properties and able to penetrate the BBB barrier. The gene discussed is MAOB; the disease is diabetes mellitus.